Cantor Fitzgerald’s BioAge Labs BIOA Stock Holding History

Cantor Fitzgerald’s Portfolio BIOA Stock Details BIOA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-200,000	Closed	-$826K	–	570
2025 Q2	$826K	Buy	+200,000	New	+$806K	0.01%	173

Other funds holding BIOA

AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Cantor Fitzgerald's BIOA Position: Q3 2025 in Review

Cantor Fitzgerald sold out of BioAge Labs (BIOA) in Q3 2025, closing a stake of 200,000 shares — an estimated $826K sold.

Cantor Fitzgerald first reported a position in BIOA in Q2 2025 and held it in 1 quarter. The position peaked at $826K in Q2 2025. 94 funds tracked by Wall St. Rank hold BIOA as of Q3 2025.

Cantor Fitzgerald reported no remaining BioAge Labs position as of Q3 2025 after selling out during the quarter.
Cantor Fitzgerald sold 200,000 BioAge Labs shares in Q3 2025, an estimated $826K.
Cantor Fitzgerald first reported a position in BioAge Labs in Q2 2025 and held it in 1 quarter.
Cantor Fitzgerald's BioAge Labs position peaked at $826K in Q2 2025.
94 funds tracked by Wall St. Rank held BioAge Labs as of Q3 2025.

Based on Cantor Fitzgerald's 13F filing for Q3 2025, filed 14 Nov 2025.